Concepedia

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder

Sender Herschorn, Jack Barkin, David Castro‐Díaz, Jeffrey Frankel, Montserrat Espuña‐Pons, Angelo E. Gousse, Matthias Stölzel, Nancy Martin, Adrie Gunther, Philip Van Kerrebroeck

Urology · 2013 · 246 citations · 16 references

DOI

Concepts

References

16

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

Vik Khullar, G. Amarenco, J.C. Angulo et al. · European Urology · 2012 · 425 citations

, , +14

Patient‐reported reasons for discontinuing overactive bladder medication

Joshua S. Benner, Michael B. Nichol, Eric S. Rovner et al. · British Journal of Urology · 2009 · 394 citations · Full text

, , +12

Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

Christopher R. Chapple, Tomasz Rechberger, P. J. MEFFAN et al. · British Journal of Urology · 2004 · 371 citations

, , +15

Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder

Victor W. Νitti, Stephen M. Auerbach, Nancy Martin et al. · The Journal of Urology · 2012 · 368 citations

, , +17

Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder

Christopher R. Chapple, Steven A. Kaplan, David Mitcheson et al. · European Urology · 2012 · 356 citations

, , +14